Viral Diseases, Bacterial Infections, and Antimicrobial Resistance
A special issue of Pathogens (ISSN 2076-0817).
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 27917
Special Issue Editor
Interests: antibiotic resistance; microbiology; antibiotics; bacterial antibiotic resistance; bacteriology; antimicrobial resistance; antibacterial activity; general microbiology; microbial isolation; environmental microbiology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Aim: To review the bacterial resistance phenomenon in pathogenic bacteria.
Scope: Survey the efforts of antibiotic stewardship globally.
Although some viral diseases have antivirals available, the most frequent respiratory viral infections are treated with antibiotics used for bacterial infections. The empiric use of antibiotics in the community and nosocomial infections is a major contributing factor in promoting bacteria's antimicrobial resistance. The use of antimicrobials and all antibiotics, including antivirals, should always follow antimicrobial stewardship rules. The inefficient use of antibiotics has created a global crisis compared to the COVID-19 pandemic. The evolving antimicrobial resistance worldwide in multidrug-resistance Gram-negative and Gram-positive bacteria affects 64.5 million annually, causes 812,000 deaths annually worldwide, and its economic impact is 400 billion US dollars.
There is an urgent need for interventions to reduce the impact of infections caused by multidrug-resistant bacteria. Natural selection for antibiotic resistance in humans, animals, and the environment requires adequate policies that different countries worldwide can use.
Dr. Eduardo Rodríguez-Noriega
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antimicrobial
- bacterial resistance
- antibiotic stewardship
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.